Loading...
Please wait, while we are loading the content...
Similar Documents
Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis
| Content Provider | Scilit |
|---|---|
| Author | Liu, Jixiang Zhong, Yulan Peng, Shanshan Zhou, Xiangxiang Gan, Xin |
| Copyright Year | 2018 |
| Description | Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis Jixiang Liu, Yulan Zhong, Shanshan Peng, Xiangxiang Zhou, Xin Gan Department of Respiratory Medicine, The First Affiliated Hospital, Nanchang University, Nanchang, China Background: PD1/PDL1 blockade is a promising treatment for patients with non-small-cell lung cancer (NSCLC). Here, we employed meta-analysis to evaluate the efficacy and safety of PD1/PDL1 blockades for previously treated NSCLC patients. Methods: Randomized clinical trials were retrieved by searching electronic databases. Data for HRs, 95% CIs for overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were extracted and pooled. Results: A total of five randomized controlled trials including 2,910 patients were included in this meta-analysis. Pooled HRs (95% CI) were 0.71 (0.63–0.79, P<0.0001) for OS and 0.86 (0.73–1.02) for PFS. In the subgroup analysis, the pooled HR (95% CI) for PFS was 0.82 (0.75–0.91, P<0.0001) in patients with high PDL1 expression, but no significant difference was seen in patients with low expression (0.97 [0.76–1.24], P=0.82). The pooled RR for treatment-related AEs of all grades was 0.32 (0.27–0.38, P<0.00001) compared with the docetaxel arm, while that for grade 3–5 treatment-related AEs in the PD1/PDL1-blockade arm was 0.16 (0.10–0.27, P<0.00001). Conclusion: PD1/PDL1 blockades enhanced OS and PFS and led to lower risk of AEs in NSCLC patients. Smoking history and wild-type EGFR were associated with extended OS. Keywords: non-small-cell lung cancer, checkpoint immunologic treatments, PD1, PDL1, meta-analysis |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284541/pdf https://www.dovepress.com/getfile.php?fileID=46698 |
| Ending Page | 8632 |
| Page Count | 10 |
| Starting Page | 8623 |
| ISSN | 11786930 |
| DOI | 10.2147/ott.s181413 |
| Journal | OncoTargets and therapy |
| Volume Number | 11 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2018-12-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Oncotargets and Therapy Oncology Pd1 Pdl1 Checkpoint Immunologic Treatments Meta-analysis Non-small-cell Lung Cancer |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology (medical) Oncology |
